Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$15.50

-0.22 (-1.40%)

, CERS

Cerus

$3.84

0.12 (3.23%)

09:18
01/08/18
01/08
09:18
01/08/18
09:18

On The Fly: Pre-market Movers

HIGHER: Immunomedics (IMMU), up 3.2% after announcing royalty funding and stock purchase agreements with Royalty Pharma... Cerus (CERS), up 4.4% after reporting preliminary Q4 product revenue... Chefs' Warehouse (CHEF), up 1% after giving FY17 revenue guidance. LOWER: Axovant Sciences (AXON), down 47.9% after announcing that its investigational drug intepirdine did not meet its primary efficacy endpoints in the Phase 2b HEADWAY and pilot Phase 2 Gait and Balance studies... Dave & Buster's (PLAY), down 11.3% after lowering FY17 revenue and EBITDA guidance... Capstone Turbine (CPST), down marginally after reporting preliminary Q3 revenue... NuVasive (NUVA), down 1% after reporting Q4 and FY17 guidance.

IMMU

Immunomedics

$15.50

-0.22 (-1.40%)

CERS

Cerus

$3.84

0.12 (3.23%)

CHEF

Chefs' Warehouse

$20.45

0.3 (1.49%)

PLAY

Dave & Buster's

$56.37

-1 (-1.74%)

CPST

Capstone Turbine

$0.85

0.0176 (2.13%)

NUVA

NuVasive

$61.01

0.09 (0.15%)

AXON

Axovant Sciences

$5.37

0.13 (2.48%)

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 26

    Feb

  • 25

    Jun

IMMU Immunomedics
$15.50

-0.22 (-1.40%)

12/06/17
JEFF
12/06/17
NO CHANGE
JEFF
Buy
Immunomedics breast cancer data continue to look 'very solid,' says Jefferies
Jefferies analyst Matthew Andrews says the totality of Immunomedics' Phase II breast cancer data for IMMU-132 "continue to look very solid." Importantly, there was no clinically meaningful decrease in objective response rate per blinded central review, Andrews tells investors in a research note after the company announced updated results. The analyst reiterates a Buy rating and believes the data is sufficient to support FDA accelerated approval.
11/14/17
COWN
11/14/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics drug survival rate disappointing but approval likely, says Cowen
Cowen analyst Phil Nadeau said the overall survival rate for Immunomedics' IMMU-132 showed a decrease, which was disappointing, but the response rate is still well above the current standard of care. As a result, the analyst believes it still appears likely to get accelerated FDA approval. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
11/14/17
JEFF
11/14/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies disagrees with yesterday's selloff in Immunomedics
Immunomedics closed down 19% yesterday largely due to interim overall survival data for IMMU-132 and concerns the FDA will require Phase III overall survival data for approval, Jefferies analyst Matthew Andrews tells investors in a research note. The analyst disagrees, and keeps a Buy rating on the shares with a $16 price target. The progression-free survival is the Phase III Special Protocol Assessment's primary endpoint, while the overall survival data may ultimately be confounded by patients' use of other drugs after progression, Andrews tells investors in a research note. Precedent for objective response rate/duration of response exists with FDA breakthrough therapy approvals of 12 solid tumor drugs, some with less robust efficacy than IMMU-132, the analyst adds.
11/13/17
WELS
11/13/17
NO CHANGE
Target $14
WELS
Outperform
Immunomedics weakness a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough said weakness in Immunomedics is a buying opportunity following review of SABCS abstract data for IIMU132 in TNBC saying he believes the data supports accelerated approval. Birchenough rates Immunomedics an Outperform with a $14 price target.
CERS Cerus
$3.84

0.12 (3.23%)

05/23/17
CANT
05/23/17
NO CHANGE
Target $7
CANT
Overweight
Cerus price target lowered to $7 from $9 at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier lowered his price target for Cerus to $7 following the announced platelet additive Solution supply shortage. The analyst keeps an Overweight rating on the shares.
01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
04/17/17
COWN
04/17/17
NO CHANGE
Target $7
COWN
Outperform
Cerus price target lowered to $7.00 from $9.50 at Cowen
Cowen analyst Joshua Jennings lowered his price target on Cerus to $7.00 from $9.50 but believes the company is well positioned to capitalize on its market development efforts supporting the U.S. platelet opportunity. Jennings believes the INTERCEPT pathogen inactivation system will eventually become the gold standard for blood transfusion safety worldwide for plasma, platelets, and red blood cells. Jennings maintained his Outperform rating on Cerus shares.
CHEF Chefs' Warehouse
$20.45

0.3 (1.49%)

05/15/17
LOOP
05/15/17
INITIATION
Target $18
LOOP
Buy
Chefs' Warehouse initiated with a Buy at Loop Capital
Loop Capital analyst Andrew Wolf started Chefs' Warehouse with a Buy rating and $18 price target. The analyst views the company as well positioned now that its protein segment has stabilized.
04/07/17
04/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. FedEx (FDX) initiated with a Buy at Loop Capital. 2. Apache (APA) initiated with a Hold at Stifel. 3. Symantec (SYMC) resumed with a Market Perform at Wells Fargo. 4. MidWestOne (MOFG) initiated with a Neutral at Piper Jaffray. 5. Chefs' Warehouse (CHEF) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/17
BMOC
11/13/17
UPGRADE
BMOC
Outperform
Chefs' Warehouse upgraded to Outperform from Market Perform at BMO Capital
11/13/17
BMOC
11/13/17
UPGRADE
Target $23
BMOC
Outperform
Chefs' Warehouse upgraded to Outperform at BMO on improving expense leverage
As reported earlier, BMO Capital analyst Kelly Bania upgraded Chefs' Warehouse to Outperform from Market Perform and raised her price target to $23 from $18. Bania says she believes that the company can reach at least a 6% EBITDA margin in the coming years relative to 4.9% in 2017, saying the progress is more realistic given the potential for improving expense leverage. The analyst also attributes the price target revision to the accretive impact of the Fells Point acquisition.
PLAY Dave & Buster's
$56.37

-1 (-1.74%)

12/07/17
ADAM
12/07/17
NO CHANGE
Target $70
ADAM
Buy
Dave & Buster's Q3 results better than feared, says Canaccord
Canaccord analyst Lynne Collier said Dave & Buster's Q3 results were mixed, but better than feared. The analyst said the outlook for the company remains strong and that guidance appears conservative. She expects new store performance to remain impressive, likes the different experience model, believes the company can sustain double digit unit growth, and views valuation as attractive. Collier reiterated her Buy rating and $70 price target on Dave & Buster's shares.
12/06/17
RHCO
12/06/17
NO CHANGE
Target $80
RHCO
Buy
Dave & Buster's price target lowered to $80 from $88 at SunTrust
SunTrust analyst Jake Bartlett lowered his price target on Dave & Buster's to $80 following Q3 results, which he says were "not pretty, but enough to assuage investor concerns about decelerating SSS". Bartlett says that while Q4 comps started out weak, a holiday calendar shifts should support a recovery. The analyst keeps his Buy rating, noting that the strong game lineup and new VR platform should accelerate amusement SSS in FY18, while also calling the company's "aggressive" food initiatives "encouraging".
12/22/17
MAXM
12/22/17
NO CHANGE
MAXM
Buy
Maxim names Dave & Buster's, Domino's and Del Taco as top 2018 restaurant picks
Maxim analyst Stephen Anderson expects the Tax Cut and Jobs Act to benefit some restaurant names more than others, calling out Habit Restaurants (HABT), Chipotle (CMG), and Zoe's Kitchen (ZOES), Dave & Buster's (PLAY), Domino's Pizza (DPZ) and Del Taco (TACO) as among those that may benefit "disproportionately" compared to sector peers. Anderson identifies Dave & Buster's, Domino's and Del Taco as his top restaurant picks for 2018 and keeps Buy ratings on all three. He also raised his price target on D&B to $97 from $84, on Domino's to $240 from $230 and on Del Taco to $20 from $19.
01/03/18
RHCO
01/03/18
NO CHANGE
Target $95
RHCO
Buy
Dave & Buster's price target raised to $95 from $80 at SunTrust
SunTrust analyst Jake Bartlett raised his price target on Dave & Buster's to $95 as part of his "Buy The Tax News" research note on Restaurants. Bartlett says the company is "one of the strongest unit growth stories in restaurants, driven by strong new unit economics and improved access to real estate", with store growth accelerating 15.2% last year and forecast to rise another 13-14% in 2018. The analyst says that despite this dynamic, the stock trades in-line with slower growing full-service peers, reflecting investor concerns about decelerating SSS which could be ameliorated by accelerating tax-reform driven industry-wide demand.
CPST Capstone Turbine
$0.85

0.0176 (2.13%)

09/18/17
ROTH
09/18/17
UPGRADE
Target $2
ROTH
Buy
Capstone Turbine upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst Craig Irwin upgraded Capstone Turbine to Buy from Neutral and raised his price target on the shares to $2 from 65c, as he believes recent storm activity in the U.S. and the Caribbean should support rebounding revenue. The analyst sees precedents from Hurricane Sandy, where Capstone saw strong uptick in activity across the N.Y. metropolitan area, and $10M incremental demand over the next 18-24 months. With Florida, Texas, and the Caribbean affected by recent storms, Irwin estimates there could be as much as $30M incremental demand.
09/18/17
HCWC
09/18/17
NO CHANGE
HCWC
Buy
Capstone Turbine joint vernture should boost sales, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal said the Capstone Energy Finance joint venture will allow the company to target a larger potential customer base, and believes Capstone is positioned favorably and should be able to grow its market share in the growing market. Dayal maintained a Buy rating and $2 price target on shares.
10/04/17
10/04/17
UPGRADE
Target $2

Outperform
Capstone Turbine upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Colin Rusch upgraded Capstone Turbine to Outperform from Perform, with a $2 price target. The analyst believes the company has effectively rationalized its overhead while working through a difficult period for demand. At the same time, with revenue approaching $100M annually, the shares are trading at an enterprise value of $24M including $10M in net cash, he adds. Rusch anticipates order activity to pick up and estimates the company will reach EBITDA break-even in FY19 as that order activity translates into sales growth.
10/04/17
OPCO
10/04/17
UPGRADE
OPCO
Outperform
Capstone Turbine upgraded to Outperform from Perform at Oppenheimer
NUVA NuVasive
$61.01

0.09 (0.15%)

12/15/17
PIPR
12/15/17
NO CHANGE
Target $90
PIPR
Overweight
NuVasive's new lateral ALIF system underappreciated, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views NuVasive's new lateral anterior lumbar interbody fusion procedure as an underappreciated revenue driver for the company. This as an important introduction for NuVasive as it finally allows the company to access the lower lumbar region with less invasiveness, O'Brien tells investors in a research note. He notes the product will allow NuVasive to compete head-to-head with Medtronic's (MDT) OLIF procedure, which he believes has grown quickly. O'Brien sees the lateral ALIF system adding $30M-$50M to NuVasive sales over the next three to four years, helping to push the stock higher. He keeps an Overweight rating on the stock with a $90 price target.
12/21/17
JPMS
12/21/17
NO CHANGE
JPMS
Overweight
NuVasive among biggest beneficiaries in MedTech from tax reform, says JPMorgan
JPMorgan analyst Robbie Marcus noted that NuVasive announced that it estimates tax law changes should drop its non-GAAP tax rate into the "low 20% range" in 2018, which he said makes it one of the biggest beneficiaries in the MedTech sector from U.S. tax reform. However, he also thinks the tax benefits have been well telegraphed and that much of the expected benefit is already factored into the stock. He maintains an Overweight rating on NuVasive shares.
12/28/17
PIPR
12/28/17
NO CHANGE
PIPR
Piper says own K2M, NuVasive into January conference
Piper Jaffray analyst Matt O'Brien recommends owning shares of K2M Group (KTWO) and NuVasive (NUVA) into a competitor conference that begins on January 8. The analyst is cautious on Zimmer Biomet (ZBH) into the conference. K2M and NuVasive are names to own going into the conference as both will meet or beat Q4 revenue estimates, O'Brien tells investors in a research note. He sees a favorable 2018 outlook for both companies as well as room for multiple expansion. On Zimmer, which the analyst downgraded recently, O'Brien continues to believe the company's turnaround will take longer than investors realize.
01/04/18
NEED
01/04/18
UPGRADE
Target $71
NEED
Buy
NuVasive upgraded to Buy from Underperform at Needham
As reported earlier, Needham analyst Mike Matson upgraded NuVasive two notches, to Buy from Underperform, and set a $71 price target on the shares. Matson says consensus revenue and EPS estimates have declined to more realistic and "likely conservative" levels, while the company's acquisitions of Vertera and SafePassage are likely not factored into consensus. The analyst also expects a 15% increase in NuVasive EPS as a result of the "significant benefit" from lower U.S. corporate tax rates.
AXON Axovant Sciences
$5.37

0.13 (2.48%)

12/21/17
12/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PG&E (PCG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Shelby Tucker stating that the company's "unexpected" decision to suspend its dividend suggests greater risk than he had assumed regarding the regulatory treatment of the California wildfires in October. 2. ConocoPhillips (COP) downgraded to Outperform from Focus List at Scotia Howard Weil. 3. Axovant Sciences (AXON) downgraded to Hold from Buy at Jefferies with analyst Michael Yee saying the company needs "more interesting" in-licensed compounds to renew investor interest in 2018 and to demonstrate the new CEO can drive shareholder value. 4. Lazard (LAZ) downgraded to Neutral from Buy at Buckingham with analyst James Mitchell saying he sees little operating leverage from the tax rate cut and said weakening restructuring revenues will be a drag on growth. 5. SunTrust (STI) downgraded to Neutral from Outperform at Wedbush with analyst Peter Winter citing valuation with the shares up 19% year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/21/17
JEFF
12/21/17
DOWNGRADE
Target $6
JEFF
Hold
Axovant Sciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee downgraded Axovant Sciences to Hold and cut his price target for the shares to $6 from $12. The company needs "more interesting" in-licensed compounds to renew investor interest in 2018 and to demonstrate the new CEO can drive shareholder value, Yee tells investors in a research note. The analyst views the stock's risk/reward as balanced at current levels.
09/27/17
BARD
09/27/17
DOWNGRADE
Target $6
BARD
Neutral
Axovant Sciences downgraded to Neutral, failure a 'death blow,' says Baird
Baird analyst Brian Skorney downgraded Axovant Sciences to Neutral from Outperform saying the failure of the Phase 3 MINDSET study in Alzheimer's this morning is a "death blow" to his thesis. The analyst removed all Alzheimer's sales for intepirdine of up to $3.5B at peak from his model and slashed Axovant's price target to $6 from $29.
09/27/17
HCWC
09/27/17
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright reiterates Buy on Axovant, says look beyond Mindset
Following the failure in Alzheimer's, H.C. Wainwright analyst Andrew Fein encourages investors to look beyond the Mindset trial and focus on the four compounds Axovant Sciences has in the clinic. He believes readouts later this year in Lewy bodies and Parkinson's disease dementia may comprise the main value drivers for Axovant moving forward. The company's core competence resides in its ability to identify and in-license underappreciated and undervalued assets, Fein tells investors in a research note partially titled "'Skyfall' is Not the End." He lowered his price target on the shares to $11 from $35 and reiterates a Buy rating on the name.

TODAY'S FREE FLY STORIES

CDAY

Ceridian

$34.31

-0.885 (-2.51%)

05:16
05/23/18
05/23
05:16
05/23/18
05:16
Recommendations
Ceridian analyst commentary  »

Ceridian reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDSO

Medidata

$75.53

-0.45 (-0.59%)

05:11
05/23/18
05/23
05:11
05/23/18
05:11
Recommendations
Medidata analyst commentary  »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VIRT

Virtu Financial

$29.10

-0.7 (-2.35%)

05:03
05/23/18
05/23
05:03
05/23/18
05:03
Initiation
Virtu Financial initiated  »

Virtu Financial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRO

Kronos Worldwide

$24.77

-0.165 (-0.66%)

04:59
05/23/18
05/23
04:59
05/23/18
04:59
Upgrade
Kronos Worldwide rating change  »

Kronos Worldwide upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$25.64

0.04 (0.16%)

, JWN

Nordstrom

$45.79

-0.05 (-0.11%)

04:56
05/23/18
05/23
04:56
05/23/18
04:56
Downgrade
DSW, Nordstrom rating change  »

DSW downgraded to Hold…

DSW

DSW

$25.64

0.04 (0.16%)

JWN

Nordstrom

$45.79

-0.05 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PLAB

Photronics

$9.05

0.6 (7.10%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Photronics to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TMO

Thermo Fisher

$217.88

1.2 (0.55%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Thermo Fisher to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

CAFD

8point3 Energy

$12.19

(0.00%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
8point3 Energy to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WST

West Pharmaceutical

$90.09

-0.04 (-0.04%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
West Pharmaceutical management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

FMBI

First Midwest

$26.40

0.25 (0.96%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
First Midwest management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SRDX

Surmodics

$49.10

0.8 (1.66%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Surmodics management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

OTEX

OpenText

$34.21

0.11 (0.32%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

FOMC Minutes to be…

WD

Walker & Dunlop

$56.00

-0.1 (-0.18%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

WWE

WWE

$56.88

-0.98 (-1.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BMCH

BMC Stock Holdings

$19.75

-0.7 (-3.42%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
BMC Stock Holdings management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

LOGI

Logitech

$40.86

0.15 (0.37%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Logitech management to meet with Citi »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

MTOR

Meritor

$21.94

-0.2 (-0.90%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Meritor management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Jun

GGG

Graco

$46.70

-0.64 (-1.35%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Graco management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SSRM

SSR Mining

$10.28

-0.02 (-0.19%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SSR Mining management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.05

-0.55 (-0.91%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

QTM

Quantum

$3.65

0.025 (0.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

WERN

Werner

$38.30

-0.7 (-1.79%)

, USAK

USA Truck

$23.19

-3.3 (-12.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Wolfe Research to hold a conference »

11th Annual Global…

WERN

Werner

$38.30

-0.7 (-1.79%)

USAK

USA Truck

$23.19

-3.3 (-12.46%)

LKQ

LKQ Corp.

$30.14

-0.62 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

, BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SunTrust to hold a bus tour »

Casino Bus tour travels…

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

CZR

Caesars

$12.65

-0.2 (-1.56%)

RRR

Red Rock Resorts

$34.09

-0.54 (-1.56%)

LGND

Ligand

$187.19

1.95 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.